Clarity Pharmaceuticals (ASX:CU6) said it has signed a large-scale manufacturing supply agreement for copper-64 with Theragenics, according to a Wednesday Australian bourse filing.
The company said the agreement relates to Theragenics' 134,000-square-foot production facility near Atlanta, Georgia, which houses 14 cyclotrons for centralized, large-scale copper-64 (Cu-64) production.
The supply agreement is ahead of the anticipated commercial launch of Cu-64-SAR-bisPSMA, subject to successful completion of Clarity's phase three registrational trials and subsequent Food and Drug Administration (FDA) new drug application (NDA) approval, the filing added.